XML 59 R44.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Collaborative Agreements Collaborative Agreements (Details) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Aug. 07, 2015 USD ($) product | Nov. 14, 2014 | Sep. 30, 2013 USD ($) | Dec. 31, 2015 USD ($) | Sep. 30, 2015 USD ($) | Jun. 30, 2015 USD ($) | Mar. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Sep. 30, 2014 USD ($) | Jun. 30, 2014 USD ($) | Mar. 31, 2014 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Dec. 31, 2013 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements |  |  |  | $ 1,820,643 | $ 16,475,083 | $ 4,335,236 | $ 4,245,571 | $ 1,758,108 | $ 1,114,952 | $ 3,107,781 | $ 1,435,727 | $ 26,876,533 | $ 7,416,568 | $ 9,239,547
Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |
MedImmune | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 27,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Anticipated development and regulatory event based payment receivable milestones | $ 700,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional products | product | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements |  |  |  |  |  |  |  |  |  |  |  | 16,000,000 |  |
Deferred revenue |  |  |  | 13,000,000 |  |  |  |  |  |  |  | 13,000,000 |  |
Accounts receivable |  |  |  | 1,500,000 |  |  |  |  |  |  |  | 1,500,000 |  |
Roche | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  | 10,000,000 |  |  |  |  |  |  |  |  |  |  |
Anticipated development and regulatory event based payment receivable milestones |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  | 3,000,000 |  |
Revenue under collaborative research and development arrangements |  |  |  |  |  |  |  |  |  |  |  | 10,800,000 | 7,400,000 |
Deferred revenue |  |  |  | 166,000 |  |  |  | 3,200,000 |  |  |  | 166,000 | 3,200,000 |
Accounts receivable |  |  |  | $ 1,600,000 |  |  |  | $ 2,300,000 |  |  |  | 1,600,000 | $ 2,300,000 |
Length of period after date of product first commercial sale to determine agreement in effect terms |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Previously deferred revenue recognized |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |
INO-3112 | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
INO 1800 | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  | $ 3,400,000 |  |  |  |  |  |  |  |  |  |  |
INO 5150 | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  | 5,000,000 |  |  |  |  |  |  |  |  |  |  |
INO 5150 | Roche | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period after notice when termination is effective |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |
Nonsoftware License Arrangement | License To Research Collaboration Products | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, additions | $ 12,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Nonsoftware License Arrangement | Option Right | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, additions |  |  | 1,500,000 |  |  |  |  |  |  |  |  |  |  |
Nonsoftware License Arrangement | Joint Steering Committee Obligation | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, additions |  |  | $ 155,000 |  |  |  |  |  |  |  |  |  |  |

X
- Definition Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones + References No definition available. + Details
Name: | ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Length of Period After Date of Product First Commercial Sale to Determine Agreement in Effect Terms + References No definition available. + Details
Name: | ino_CollaborationAgreementLengthofPeriodAfterDateofProductFirstCommercialSaletoDetermineAgreementinEffectTerms
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreements, Upfront Payment Received + References No definition available. + Details
Name: | ino_CollaborativeAgreementsUpfrontPaymentReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Additional Products + References No definition available. + Details
Name: | ino_NumberOfAdditionalProducts
Namespace Prefix: | ino_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Under Collaborative Research and Development Arrangements + References No definition available. + Details
Name: | ino_RevenueUnderCollaborativeResearchandDevelopmentArrangements
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Termination Notice Effective, Days Subsequent to Notice + References No definition available. + Details
Name: | ino_TerminationNoticeEffectiveDaysSubsequenttoNotice
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.9) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.5) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Article 5 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ino_MedImmuneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ino_HoffmanLaRocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_INO3112Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_INO1800Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_INO5150Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_NonsoftwareLicenseArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_LicenseToResearchCollaborationProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_OptionRightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_JointSteeringCommitteeObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |